内镜下袖状胃成形术治疗1级和2级肥胖(MERIT):一项前瞻性、多中心、随机试验
MERIT试验在美国9个中心随机分组209例21-65岁1级或2级肥胖患者,按1:1.5接受ESG联合生活方式干预(ESG组85例)或单纯生活方式干预(对照组124例)。52周时ESG组平均多余体重减少百分比为49.2%(SD 32.0),对照组为3.2%(18.6)(p<0.0001);ESG组77%(59/77)达到25%或以上多余体重减少,对照组为12%(13/110)(p<0.0001)。104周时ESG组68%(41/60)维持25%或以上多余体重减少。ESG相关严重不良事件发生于131例中的3例(2%),无死亡、无需重症监护或手术。作者认为ESG应被考虑作为1级或2级肥胖患者的协同减重干预。
要点
- 52周时ESG组平均多余体重减少49.2%(SD 32.0),对照组3.2%(18.6),p<0.0001。
- 52周时ESG组平均总体重减少13.6%(8.0),对照组0.8%(5.0),p<0.0001。
- 52周时ESG组77%(59/77)达到25%或以上多余体重减少,对照组12%(13/110),p<0.0001。
- 104周时ESG组68%(41/60)维持25%或以上多余体重减少。
- ESG相关严重不良事件发生于131例中的3例(2%),无死亡、无需重症监护或手术。
适用人群与场景
- 年龄21-65岁、1级或2级肥胖、同意遵守终身饮食限制的个体,来自美国9个中心。
处置流程与药物剂量
- ESG组接受内镜下袖状胃成形术联合生活方式干预(低热量饮食和体力活动),52周时可能行再次收紧。
- 对照组接受单纯生活方式干预,52周时可能交叉接受ESG。
- ESG组主要随访至104周。
研究设计与关键结果
- 研究类型:前瞻性、多中心、随机临床试验,美国9个中心,纳入209例,随机1:1.5分为ESG组(n=85)和对照组(n=124)。
- 主要终点52周平均多余体重减少百分比:ESG组49.2%(SD 32.0) vs 对照组3.2%(18.6),p<0.0001。
- 52周平均总体重减少百分比:ESG组13.6%(8.0) vs 对照组0.8%(5.0),p<0.0001。
- 52周达到25%或以上多余体重减少:ESG组59/77(77%) vs 对照组13/110(12%),p<0.0001。
- 52周代谢合并症改善:ESG组51例中41例(80%)一项或以上改善、6例(12%)恶化;对照组62例中28例(45%)改善、31例(50%)恶化。
- 104周维持25%或以上多余体重减少:ESG组41/60(68%)。
- 安全性:ESG相关严重不良事件3/131(2%),无死亡、无需重症监护或手术。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ESG应被考虑作为1级或2级肥胖患者的协同减重干预。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Endoscopic sleeve gastroplasty (ESG) is an endolumenal, organ-sparing therapy for obesity, with wide global adoption. We aimed to explore the efficacy and safety of ESG with lifestyle modifications compared with lifestyle modifications alone.
METHODS: We conducted a randomised clinical trial at nine US centres, enrolling individuals aged 21-65 years with class 1 or class 2 obesity and who agreed to comply with lifelong dietary restrictions. Participants were randomly assigned (1:1·5; with stratified permuted blocks) to ESG with lifestyle modifications (ESG group) or lifestyle modifications alone (control group), with potential retightening or crossover to ESG, respectively, at 52 weeks. Lifestyle modifications included a low-calorie diet and physical activity. Participants in the primary ESG group were followed up for 104 weeks. The primary endpoint at 52 weeks was the percentage of excess weight loss (EWL), with excess weight being that over the ideal weight for a BMI of 25 kg/m2. Secondary endpoints included change in metabolic comorbidities between the groups. We used multiple imputed intention-to-treat analyses with mixed-effects models. Our analyses were done on a per-protocol basis and a modified intention-to-treat basis. The safety population was defined as all participants who underwent ESG (both primary and crossover ESG) up to 52 weeks.
FINDINGS: Between Dec 20, 2017, and June 14, 2019, 209 participants were randomly assigned to ESG (n=85) or to control (n=124). At 52 weeks, the primary endpoint of mean percentage of EWL was 49·2% (SD 32·0) for the ESG group and 3·2% (18·6) for the control group (p<0·0001). Mean percentage of total bodyweight loss was 13·6% (8·0) for the ESG group and 0·8% (5·0) for the control group (p<0·0001), and 59 (77%) of 77 participants in the ESG group reached 25% or more of EWL at 52 weeks compared with 13 (12%) of 110 in the control group (p<0·0001). At 52 weeks, 41 (80%) of 51 participants in the ESG group had an improvement in one or more metabolic comorbidities, whereas six (12%) worsened, compared with the control group in which 28 (45%) of 62 participants had similar improvement, whereas 31 (50%) worsened. At 104 weeks, 41 (68%) of 60 participants in the ESG group maintained 25% or more of EWL. ESG-related serious adverse events occurred in three (2%) of 131 participants, without mortality or need for intensive care or surgery.
INTERPRETATION: ESG is a safe intervention that resulted in significant weight loss, maintained at 104 weeks, with important improvements in metabolic comorbidities. ESG should be considered as a synergistic weight loss intervention for patients with class 1 or class 2 obesity. This trial is registered with ClinicalTrials.gov, NCT03406975.
FUNDING: Apollo Endosurgery, Mayo Clinic.
参考来源
- Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 2022. PMID: 35908555. doi:10.1016/S0140-6736(22)01280-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。